Primary malignant melanoma of the esophagus is a rare illness accounting for 0.1-0.2% of malignant diseases of the esophagus; however, the incidence of the disease appears to be rising. The average survival time is between 10 and 15 months. The authors describe the 25 month follow up of a patient with primary malignant melanoma of the esophagus which was treated with endoscopic ablation followed by interferon therapy. No other focus was found and the patient is undergoing regular endoscopic check-ups, currently without any problems.

• MeSH
• ezofágoskopie metody   MeSH
• hodnocení rizik MeSH
• interferony aplikace a dávkování   MeSH
• jehlová biopsie MeSH
• kombinovaná terapie MeSH
• lidé středního věku MeSH
• lidé MeSH
• melanom diagnóza   patologie   terapie   MeSH
• nádory jícnu diagnóza   patologie   terapie   MeSH
• následné studie MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• kazuistiky MeSH
• Názvy látek
• interferony MeSH

BACKGROUND: Malignant melanoma in the gastrointestinal tract may be primary or metastatic. Mucosal melanoma is a quite rare and aggressive disease, growing hidden and diagnosed with a certain delay which makes treatment difficult. CASE REPORT: The authors present the first patient with c-kit exon 11 mutated primary esophageal melanoma treated with oral tyrosine kinase inhibitor masitinib. A 55-year-old-man presented with esophageal melanoma metastising into visceral organs and to the brain. The patient showed objective and clinical significant therapeutic response to masitinib. After initiation of masitinib, dysphagia and odynophagia disappeared within 1 week. Following 1 month of treatment, computed tomography showed a regression in the number and size of brain metastatic lesions and regression in visceral lesions. This therapeutic response, despite the aggressive disease on treatment initiation, effectively enabled the patient to have 6 months of quality life. CONCLUSION: This report corroborates the plausibility of treating advanced melanoma carrying a mutation of KIT with masitinib. It also raises the question of masitinib treatment beyond progression. Additionally, the observed masitinib treatment effect on the brain suggests accumulation of therapeutically relevant concentration of masitinib in the central nervous system. This observation has possible ramifications for treatment of intracranial neoplasms.

• Klíčová slova
• esophageal melanoma, masitinib, targeted therapy,
• MeSH
• benzamidy MeSH
• exony MeSH
• fatální výsledek MeSH
• inhibitory proteinkinas terapeutické užití   MeSH
• lidé středního věku MeSH
• lidé MeSH
• melanom farmakoterapie   sekundární   MeSH
• mutace genetika   MeSH
• nádory jícnu farmakoterapie   MeSH
• nádory mozku farmakoterapie   sekundární   MeSH
• piperidiny MeSH
• protoonkogenní proteiny c-kit genetika   MeSH
• pyridiny MeSH
• thiazoly terapeutické užití   MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• kazuistiky MeSH
• Názvy látek
• benzamidy MeSH
• inhibitory proteinkinas MeSH
• masitinib MeSH Prohlížeč
• piperidiny MeSH
• protoonkogenní proteiny c-kit MeSH
• pyridiny MeSH
• thiazoly MeSH

The author presents an observation of a rare malignant melanoma of oesophagus, its radiographic picture being similar to sarcoma. The primary melanoblastoma may also affect other internal organs.

• MeSH
• lidé MeSH
• nádory jícnu * diagnóza   diagnostické zobrazování   MeSH
• radiografie MeSH
• senioři MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• Publikační typ
• časopisecké články MeSH
• kazuistiky MeSH